Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
VTGN similar filings
- 22 Jul 22 VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial
- 23 Jun 22 VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results
- 22 Jun 22 VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
- 9 Jun 22 Regulation FD Disclosure
- 5 May 22 VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
- 3 May 22 VistaGen Appoints Reid Adler as Chief Legal Officer
- 21 Apr 22 VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
Filing view
External links